<DOC>
	<DOCNO>NCT02681432</DOCNO>
	<brief_summary>Randomized clinical trial ass efficacy close abdomen hyperthermia intraperitoneal chemotherapy paclitaxel ovarian cancer .</brief_summary>
	<brief_title>Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel Advanced Ovarian Cancer</brief_title>
	<detailed_description>Randomized clinical trial perform woman epithelial primary ovarian cancer ( stage FIGO II , III IV ) tumor recurrence . A cytoreductive surgery perform patient include trial , assign randomization : - HIPEC-arm : cytoreductive surgery hyperthermic intraperitoneal chemotherapy paclitaxel ( 175 mg / m2 ) 60 minute temperature 42-43º degree ; follow postoperative systemic IV chemotherapy carboplatin ( AUC=6 ) paclitaxel ( 175 mg/m2 ) 6 cycle . - No HIPEC-arm : Cytoreductive surgery follow postoperative systemic IV chemotherapy carboplatin ( AUC=6 ) paclitaxel ( 175 mg/m2 ) 6 cycle .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Women histologically confirm epithelial ovarian cancer ( stage II / III / IV disease FIGO ) tumor recurrence ( woman childbearing age need negative pregnancy test ) Complete cytoreduction : Index CC0/CC1 cytoreduction ( residual tumor size surgery , visible ( CC0 ) less 0.25 cm ( CC1 ) ) No extraabdominal tumor disease Absence heart failure . Adequate renal hepatic function Eastern Cooperative Oncology Group performance status 02 Karnofsky performance status ≥ 70 % Patients unresectable tumor incomplete cytoreduction . Contraindications treatment paclitaxel : patient severe hypersensitivity paclitaxel excipients , pregnancy lactation patient baseline neutrophil count &lt; 1.500/mm3 ( &lt; 1.000/mm3 patient Kaposi sarcoma ) . Paclitaxel also contraindicate patient concurrent severe infection . Extraabdominal metastasis unresectable liver metastasis Presence malignant tumor disease . Multisegmental complete bowel obstruction . Patients severe medical problem preclude compliance study unacceptable risk Patients refuse treatment consent participate study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIPEC</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>peritoneal carcinomatosis</keyword>
</DOC>